Ask us about access to our new physician portal for Web-Based ordering and results access via the Sunquest Physician Portal powered by Atlas.
Clinicians and their designated office staff can access our web based reporting system not only for online results access, but can also place their orders for laboratory testing electronically and ease of requisition completion and printing.
To obtain your Access LogOn and or for more information regarding the portal, please contact Tanya Odle at (918) 712-5571 extension 200.
TML/Atlas Informational PDF
TML has acquired the Hologic Cervista HTA (High Throughput Automation) system and the Hologic Gen-Probe Panther.
The HTA system is FDA approved and automates the DNA extraction and detection steps of the Hologic Cervista HR HPV test. The HTA provides higher throughput, improved chain of custody, and accurate results.
The Hologic Gen-Probe Panther is a fully-automated, random access sampling instrument which is currently FDA approved to perform the Aptima CT/NG test and the new Trichomonas vaginalis nucleic acid amplification test. A single one milliliter aliquot from a patient’s Thin Prep Pap Test vial can be tested for up to three different assays simultaneously on the Panther.
FDA approval is currently pending for the Aptima HPV test. A genotyping assay for HPV 16, 18, 45 and HSV-1 and HSV-2 assays are currently in development.
In August of 2016, the Tulsa Medical Lab Molecular Department completed validation studies to apply the Hologic Aptima HPV Genotyping Assay to head and neck fine needle aspiration samples.
Head and neck cancer is the 6th most common cancer worldwide with over 550,000 new cases each year. 90% of head and neck cancers are squamous cell carcinoma.
Currently, 72% of the oropharyngeal squamous cell carcinomas in the United States are HPV-related. HPV 16 is responsible for 90 to 95% of those cancers. Experts agree that E6/E7 detection of mRNA transcripts is generally regarded as the gold standard for HPV detection.
The Aptima HPV Genotyping Assay targets the E6/E7 mRNA of HPV 16 and 18/45 which makes it a superlative choice for determining the presence of HPV 16 in fine needle aspiration samples.
The 5 year survival rate for patients with HPV positive squamous cell carcinoma is greater than 80% comparted to 40% for patients with HPV negative head and meck squamous cell carcinoma.
For more information on this exciting and affordable test, please contact the molecular department at 918-481-7857.
The Cellient™ Automated Cell Block System is the first fully-automated cell blocking system built on ThinPrep® technology. It improves capture by maximizing cellularity even from small/scanty samples. It also improves presentation by maintaining crisp, clear cellular architectural detail with concentrations of cells within the block.
This system allows for review of cytology and cell block simultaneously. It improves consistency by being fully automated with minimal operator dependency, resulting in less cross-contamination risk along with consistently rapid processing time (45 minutes or less).